ALKERMES 1 RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHSat, 04 Apr 2026 03:06:01 +0200https://images.finanzen.net/images/finanzen_net_neu.gifALKERMES 1 RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netAlkermes präsentierte QuartalsergebnisseFri, 27 Feb 2026 06:35:07 +0100https://www.finanzen.net/nachricht/aktien/alkermes-praesentierte-quartalsergebnisse-15521415Alkermes hat am 25.02.2026 die Geschäftsergebnisse zum jüngsten Jahresviertel vorgestellt.Es wurde ein Gewinn je Aktie von 0,29 USD präsentiert. Im Vorjahresquartal hatte Alkermes ein EPS von 0,880 USD je Aktie vermeldet.Umsatzseitig ...

]]>https://www.finanzen.net/nachricht/aktien/alkermes-praesentierte-quartalsergebnisse-15521415Ausblick: Alkermes veröffentlicht Zahlen zum vergangenen QuartalTue, 24 Feb 2026 07:01:06 +0100https://www.finanzen.net/nachricht/aktien/ausblick-alkermes-veroeffentlicht-zahlen-zum-vergangenen-quartal-15511449Alkermes wird am 25.02.2026 die Geschäftsergebnisse zum jüngsten Jahresviertel vorstellen.12 Analysten schätzen, dass Alkermes für das jüngste Quartal im Schnitt einen Gewinn ...

]]>https://www.finanzen.net/nachricht/aktien/ausblick-alkermes-veroeffentlicht-zahlen-zum-vergangenen-quartal-15511449Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plcWed, 19 Nov 2025 12:00:00 +0100https://www.finanzen.net/nachricht/aktien/alkermes-plc-announces-increased-offer-to-acquire-avadel-pharmaceuticals-plc-15291259

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

]]>https://www.finanzen.net/nachricht/aktien/alkermes-plc-announces-increased-offer-to-acquire-avadel-pharmaceuticals-plc-15291259Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plcWed, 19 Nov 2025 12:00:00 +0100https://www.finanzen.net/nachricht/aktien/alkermes-plc-announces-increased-offer-to-acquire-avadel-pharmaceuticals-plc-15291267

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

]]>https://www.finanzen.net/nachricht/aktien/alkermes-plc-announces-increased-offer-to-acquire-avadel-pharmaceuticals-plc-15291267Alkermes Response to Avadel AnnouncementFri, 14 Nov 2025 13:51:00 +0100https://www.finanzen.net/nachricht/aktien/alkermes-response-to-avadel-announcement-15276369

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ...

]]>https://www.finanzen.net/nachricht/aktien/alkermes-response-to-avadel-announcement-15276369Alkermes Response to Avadel AnnouncementFri, 14 Nov 2025 13:45:00 +0100https://www.finanzen.net/nachricht/aktien/alkermes-response-to-avadel-announcement-15276361

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ...

]]>https://www.finanzen.net/nachricht/aktien/alkermes-response-to-avadel-announcement-15276361Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2Wed, 12 Nov 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/alkermes-announces-positive-topline-results-from-vibrance-2-phase-2-study-of-once-daily-alixorexton-in-patients-with-narcolepsy-type-2-15266640

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 –

]]>https://www.finanzen.net/nachricht/aktien/alkermes-announces-positive-topline-results-from-vibrance-2-phase-2-study-of-once-daily-alixorexton-in-patients-with-narcolepsy-type-2-15266640Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2Wed, 12 Nov 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/alkermes-announces-positive-topline-results-from-vibrance-2-phase-2-study-of-once-daily-alixorexton-in-patients-with-narcolepsy-type-2-15266645

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 –

]]>https://www.finanzen.net/nachricht/aktien/alkermes-announces-positive-topline-results-from-vibrance-2-phase-2-study-of-once-daily-alixorexton-in-patients-with-narcolepsy-type-2-15266645Alkermes to Participate in Two Upcoming Investor ConferencesThu, 06 Nov 2025 22:00:00 +0100https://www.finanzen.net/nachricht/aktien/alkermes-to-participate-in-two-upcoming-investor-conferences-15212055

DUBLIN, Nov. 6, 2025 /PRNewswire/ -- ]]>https://www.finanzen.net/nachricht/aktien/alkermes-to-participate-in-two-upcoming-investor-conferences-15212055Alkermes to Participate in Two Upcoming Investor ConferencesThu, 06 Nov 2025 22:00:00 +0100https://www.finanzen.net/nachricht/aktien/alkermes-to-participate-in-two-upcoming-investor-conferences-15212056

DUBLIN, Nov. 6, 2025 /PRNewswire/ -- ]]>https://www.finanzen.net/nachricht/aktien/alkermes-to-participate-in-two-upcoming-investor-conferences-15212056